<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01052701</url>
  </required_header>
  <id_info>
    <org_study_id>NA_00023807</org_study_id>
    <nct_id>NCT01052701</nct_id>
  </id_info>
  <brief_title>Drug Interaction Study With Ribavirin and Abacavir in Male Subjects With Hepatitis C Who Have Failed Ribavirin Treatment</brief_title>
  <official_title>Pharmacokinetic Interactions of Ribavirin and Abacavir in Hepatitis-C Mono-infected Male Subjects Who Previously Failed Ribavirin-based Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research is being done to find out whether abacavir (Ziagen®) lowers the levels of&#xD;
      ribavirin (Ribapak®) in the body of persons taking these two drugs.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Abacavir is an anti-HIV drug that belongs to the class of nucleoside reverse transcriptase&#xD;
      inhibitors. Ribavirin is a drug used to treat hepatitis C infection. Both abacavir and&#xD;
      ribavirin are approved by the Food and Drug administration (FDA). The doses of abacavir and&#xD;
      ribavirin used in this study are also FDA approved.Some individuals who have HIV infection&#xD;
      also have hepatitis C. It is possible that they may need to take both abacavir to treat HIV&#xD;
      and ribavirin to treat hepatitis C. Recent studies suggest that abacavir decreases the level&#xD;
      of ribavirin in the body, in the blood and in cells named peripheral blood mononuclear cells&#xD;
      (PBMC's). Thus, taking ribavirin and abacavir together could lead to treatment failure for&#xD;
      hepatitis C. Therefore, it is important to understand whether ribavirin levels are affected&#xD;
      when the two medications are taken together.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ribavirin Triphosphate (RBV-TP) Intracellular Concentrations</measure>
    <time_frame>Day 56</time_frame>
    <description>Ribavirin Triphosphate (RBV-TP) intracellular concentrations.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma RBV Trough Concentrations</measure>
    <time_frame>Day 56</time_frame>
    <description>Plasma RBV trough concentrations.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Hepatitis C</condition>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>Ribavirin plus Abacavir</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ribavirin plus Abacavir Administration intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ribavirin alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ribavirin alone administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <description>Daily Ribavirin alone 400 mg in the morning (AM) and 600 mg in the afternoon (PM) orally with 12 hours between the doses (Body Weight ≤75 kg)&#xD;
OR&#xD;
Daily RBV alone 600 mg orally every 12 hours (Body Weight &gt;75 kg)</description>
    <arm_group_label>Ribavirin alone</arm_group_label>
    <other_name>Ribavirin (RBV)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin plus Abacavir (ABC)</intervention_name>
    <description>Daily Ribavirin 400 mg in AM and 600 mg in PM orally with 12 hours between the doses (Body Weight ≤75 kg)&#xD;
OR&#xD;
Daily RBV 600 mg orally every 12 hours (Body Weight &gt;75 kg)&#xD;
Plus&#xD;
Daily Abacavir 300 mg orally every 12 hours</description>
    <arm_group_label>Ribavirin plus Abacavir</arm_group_label>
    <other_name>RBV + ABC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Hepatitis C Virus (HCV) -monoinfected subjects who either successfully completed&#xD;
             (defined as cured) or previously failed RBV-based therapy for hepatitis C infection,&#xD;
             and are currently not receiving therapy for hepatitis C; at least 18-64 years of age.&#xD;
             HCV cure is defined as a sustained undetectable viral response at 24 weeks post&#xD;
             treatment.&#xD;
&#xD;
          -  Females who are not of reproductive potential (defined as women who have been&#xD;
             postmenopausal for at least 24 consecutive months or who have undergone hysterectomy,&#xD;
             bilateral oophorectomy, or bilateral tubal ligation.&#xD;
&#xD;
          -  Negative serum β- human chorionic gonadotropin (HCG)&#xD;
&#xD;
          -  Negative HIV-1 serology documented by any licensed Enzyme-linked immunoassay (ELISA)&#xD;
             test kit within 30 days prior to study entry.&#xD;
&#xD;
          -  Positive HCV antibody documented within 30 days prior to study entry.&#xD;
&#xD;
          -  Negative Human Leukocyte Antigen (HLA)-B*5701 test documented within 30 days prior to&#xD;
             study entry.&#xD;
&#xD;
          -  Ability and willingness of subject to provide a signed informed consent and comply&#xD;
             with study requirements.&#xD;
&#xD;
          -  All subjects must not participate in a conception process (e.g., active attempt to&#xD;
             impregnate, sperm donation, in vitro fertilization). If participating in sexual&#xD;
             activity that could lead to pregnancy, male subjects must take every precaution to&#xD;
             avoid risk of pregnancy for their female partners by using reliable contraception&#xD;
             (condom) while receiving study therapy and for 6 months following permanent&#xD;
             discontinuation of study therapy. Subjects will also be instructed to counsel their&#xD;
             female partners regarding fetal risk and need for appropriate contraception (e.g.,&#xD;
             hormonal, barrier) so as a secondary effort to prevent pregnancy even though the&#xD;
             female partners will not be study participants.&#xD;
&#xD;
          -  Estimated creatinine clearance ≥50 mL/minute, within 30 days prior to study entry&#xD;
&#xD;
          -  Laboratory values obtained within 30 days prior to study entry:&#xD;
&#xD;
          -  Hgb within the normal limits as defined by the reporting laboratory&#xD;
&#xD;
          -  Aspartate aminotransferase (AST), Alanine aminotransferase (ALT), and alkaline&#xD;
             phosphatase &gt;5 x upper limit of normal (ULN) as defined by the reporting laboratory.&#xD;
&#xD;
          -  Direct bilirubin ≤1.5 x ULN as defined by the reporting laboratory.&#xD;
&#xD;
          -  Follicle Stimulate Hormone (FSH) measurement elevated into the menopausal range for&#xD;
             females who report being postmenopausal for at least 24 consecutive months is required&#xD;
             at screening for all female subjects.&#xD;
&#xD;
          -  Subject has not consumed alcohol in the 48 hours prior to the administration of study&#xD;
             drugs.&#xD;
&#xD;
          -  Framingham cardiovascular disease risk score &lt;10%.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  As determined by the investigator, a significant active or previous history of&#xD;
             cardiovascular, renal, hematologic, neurologic, gastrointestinal, psychiatric,&#xD;
             endocrine, or immunologic disease (s). This inclusive of chronic illnesses such as&#xD;
             hypertension, coronary artery disease, arthritis, diabetes, any chronic&#xD;
             gastrointestinal condition that may affect drug absorption. History of chronic or&#xD;
             acute medical condition that in the opinion of the investigator would jeopardize&#xD;
             safety of subjects participating in this study. Any other medical or psychological&#xD;
             condition that might, in the opinion of the site investigator, interfere with&#xD;
             participation in the study or put subjects at undue risk.&#xD;
&#xD;
          -  History of anemia, hemoglobinopathy or any other cause of or tendency to hemolysis.&#xD;
&#xD;
          -  History of RBV-induced anemia that required dose reduction or discontinuation of RBV&#xD;
             therapy while receiving treatment for hepatitis C infection in the past. Patients who&#xD;
             required treatment with erythropoietin or blood transfusion for the management of&#xD;
             RBV-associated anemia will be excluded from participating in the study.&#xD;
&#xD;
          -  Use of prescription or over-the-counter medications, including herbal products, within&#xD;
             30 days prior to study entry that in the opinion of the investigator would preclude&#xD;
             study participation.&#xD;
&#xD;
          -  Pregnant women or men with a pregnant female partner.&#xD;
&#xD;
          -  Breast feeding&#xD;
&#xD;
          -  Active drug use or dependence that, in the opinion of the investigator, would&#xD;
             interfere with adherence to study requirements, and/or currently receiving methadone&#xD;
             replacement therapy for the treatment of substance abuse.&#xD;
&#xD;
          -  Inability of abstaining from alcohol-containing beverages for the duration of the&#xD;
             study.&#xD;
&#xD;
          -  Hospitalization or therapy for serious illness within 30 days prior to study entry as&#xD;
             judged by the investigator.&#xD;
&#xD;
          -  Known or suspected hypersensitivity reaction to study drugs or their formulations.&#xD;
&#xD;
          -  Participation in any investigational drug study within 30 days prior to study entry.&#xD;
&#xD;
          -  Active or history of gout disease.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adriana Andrade, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins Drug Development Unit</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <study_first_submitted>January 19, 2010</study_first_submitted>
  <study_first_submitted_qc>January 19, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 20, 2010</study_first_posted>
  <results_first_submitted>February 7, 2017</results_first_submitted>
  <results_first_submitted_qc>April 25, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 27, 2017</results_first_posted>
  <last_update_submitted>April 27, 2017</last_update_submitted>
  <last_update_submitted_qc>April 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Abacavir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited through general newspaper advertisements, flyers, and referral from providers specializing in hepatitis C</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Ribavirin Plus Abacavir</title>
          <description>Ribavirin plus Abacavir Administration intervention&#xD;
Ribavirin plus Abacavir: Daily Ribavirin 400 mg in the morning (AM) and 600 mg in the afternoon (PM) orally with 12 hours between the doses (Body Weight ≤75 kg)&#xD;
or&#xD;
Daily RBV 600 mg orally every 12 hours (Body Weight &gt;75 kg)&#xD;
plus&#xD;
Daily Abacavir 300 mg orally every 12 hours</description>
        </group>
        <group group_id="P2">
          <title>Ribavirin Alone</title>
          <description>Ribavirin alone administration&#xD;
Ribavirin: Daily Ribavirin alone 400 mg in AM and 600 mg in PM orally with 12 hours between the doses (Body Weight ≤75 kg)&#xD;
OR&#xD;
Daily RBV alone 600 mg orally every 12 hours (Body Weight &gt;75 kg)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ribavirin Plus Abacavir</title>
          <description>Ribavirin plus Abacavir Administration intervention&#xD;
Ribavirin plus Abacavir: Daily Ribavirin 400 mg in AM and 600 mg in PM orally with 12 hours between the doses (Body Weight ≤75 kg)&#xD;
or&#xD;
Daily RBV 600 mg orally every 12 hours (Body Weight &gt;75 kg)&#xD;
plus&#xD;
Daily Abacavir 300 mg orally every 12 hours</description>
        </group>
        <group group_id="B2">
          <title>Ribavirin Alone</title>
          <description>Ribavirin alone administration&#xD;
Ribavirin: Daily Ribavirin alone 400 mg in AM and 600 mg in PM orally with 12 hours between the doses (Body Weight ≤75 kg)&#xD;
or&#xD;
Daily RBV alone 600 mg orally every 12 hours (Body Weight &gt;75 kg)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="26"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54" lower_limit="50" upper_limit="58"/>
                    <measurement group_id="B2" value="50" lower_limit="48" upper_limit="54"/>
                    <measurement group_id="B3" value="52" lower_limit="49" upper_limit="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Ribavirin Triphosphate (RBV-TP) Intracellular Concentrations</title>
        <description>Ribavirin Triphosphate (RBV-TP) intracellular concentrations.</description>
        <time_frame>Day 56</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ribavirin Plus Abacavir</title>
            <description>Ribavirin plus Abacavir Administration intervention&#xD;
Ribavirin plus Abacavir: Daily Ribavirin 400 mg in AM and 600 mg in PM orally with 12 hours between the doses (Body Weight ≤75 kg)&#xD;
or&#xD;
Daily RBV 600 mg orally every 12 hours (Body Weight &gt;75 kg)&#xD;
plus&#xD;
Daily Abacavir 300 mg orally every 12 hours</description>
          </group>
          <group group_id="O2">
            <title>Ribavirin Alone</title>
            <description>Ribavirin alone administration&#xD;
Ribavirin: Daily Ribavirin alone 400 mg in AM and 600 mg in PM orally with 12 hours between the doses (Body Weight ≤75 kg)&#xD;
OR&#xD;
Daily RBV alone 600 mg orally every 12 hours (Body Weight &gt;75 kg)</description>
          </group>
        </group_list>
        <measure>
          <title>Ribavirin Triphosphate (RBV-TP) Intracellular Concentrations</title>
          <description>Ribavirin Triphosphate (RBV-TP) intracellular concentrations.</description>
          <units>picomoles per 10^6 cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.87" spread="12.82"/>
                    <measurement group_id="O2" value="15.93" spread="12.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma RBV Trough Concentrations</title>
        <description>Plasma RBV trough concentrations.</description>
        <time_frame>Day 56</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ribavirin Plus Abacavir</title>
            <description>Ribavirin plus Abacavir Administration intervention&#xD;
Ribavirin plus Abacavir: Daily Ribavirin 400 mg in AM and 600 mg in PM orally with 12 hours between the doses (Body Weight ≤75 kg)&#xD;
or&#xD;
Daily RBV 600 mg orally every 12 hours (Body Weight &gt;75 kg)&#xD;
plus&#xD;
Daily Abacavir 300 mg orally every 12 hours</description>
          </group>
          <group group_id="O2">
            <title>Ribavirin Alone</title>
            <description>Ribavirin alone administration&#xD;
Ribavirin: Daily Ribavirin alone 400 mg in AM and 600 mg in PM orally with 12 hours between the doses (Body Weight ≤75 kg)&#xD;
OR&#xD;
Daily RBV alone 600 mg orally every 12 hours (Body Weight &gt;75 kg)</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma RBV Trough Concentrations</title>
          <description>Plasma RBV trough concentrations.</description>
          <units>micrograms per milliliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.54" spread="1.05"/>
                    <measurement group_id="O2" value="2.60" spread="0.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Ribavirin Plus Abacavir</title>
          <description>Ribavirin plus Abacavir Administration intervention&#xD;
Ribavirin plus Abacavir: Daily Ribavirin 400 mg in AM and 600 mg in PM orally with 12 hours between the doses (Body Weight ≤75 kg)&#xD;
or&#xD;
Daily RBV 600 mg orally every 12 hours (Body Weight &gt;75 kg)&#xD;
plus&#xD;
Daily Abacavir 300 mg orally every 12 hours</description>
        </group>
        <group group_id="E2">
          <title>Ribavirin Alone</title>
          <description>Ribavirin alone administration&#xD;
Ribavirin: Daily Ribavirin alone 400 mg in AM and 600 mg in PM orally with 12 hours between the doses (Body Weight ≤75 kg)&#xD;
OR&#xD;
Daily RBV alone 600 mg orally every 12 hours (Body Weight &gt;75 kg)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>hyperglycemia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="14"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>insomnia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>hyperbilirubinemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>transaminitis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="14"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>upper respiratory infection</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="14"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Associate Director, Drug Development Unit</name_or_title>
      <organization>Johns Hopkins School of Medicine</organization>
      <phone>(410) 614-8762</phone>
      <email>ejfuchs@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

